Victoria Socha
Articles by Victoria Socha
BTK inhibitor zanubrutinib was found to be well tolerated and showed activity in patients with membranous nephropathy.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
Finerenone did not modify kidney outcomes but reduced albuminuria and risk of new-onset macroalbuminuria in patients with HF.
A trial assessed an acellular tissue engineered vessel (ATEV) compared to autologous arteriovenous fistula for hemodialysis.
Pegcetacoplan achieved significant reductions in proteinuria and C3c staining and stabilized eGFR in patients with C3G.
FLOW trial data showed semaglutide safely reduced risks of major kidney outcomes regardless of CKD severity.
A novel endothelin receptor type A selective antagonist showed a meaningful reduction in proteinuria in patients with IgAN.
Treatment of IgA nephropathy with felzartamab led to sustained proteinuria reduction and reduced eGFR decline.
BAFF and APRIL inhibitor atacicept reduced UPCR, hematuria, and Gd-IgA1 and stabilized eGFR in patients with IgAN.
A study examined the effects of semaglutide in patients with overweight/obesity and albuminuria CKD without T2D.
Data from patient charts and surveys of nephrologists shed light on the future of individualizing treatment for IgAN.
Recent research reveals tolvaptan’s role in reducing hemodialysis initiation risk in ADPKD,
Contrary to recommendations, low-dose tolvaptan may be an option for refractory hyponatremia in cirrhosis.
A study examined physician confidence and barriers to prescription of tolvaptan for the management of ADPKD.
A study investigated whether treatment with difelikefalin and tolvaptan can protect against worsening of late-stage PKD.
ESSENTIAL assessed the safety and effectiveness of tolvaptan among patients in Korea with ADPKD and CKD stages 1 to 3.
Tolvaptan increased serum sodium without causing sodium overcorrection in syndrome of inappropriate antidiuresis.
A study examined the association between gross hematuria after COVID-19 vaccination and renal prognosis in IgAN patients.
Loss-of-function phenotypic screening with LEAPFROG-powered CRISPR-cas9 is likely to identify therapeutic targets for IgAN.
ARPCs isolated from urine of IgAN patients can form renal spheroids and tubular-like structures without external cytokines.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.